Pfizer Inc (PFE.N)
29.11USD
23 May 2013
$-0.19 (-0.65%)
$29.30
$29.06
$29.31
$28.85
8,176,384
7,729,765
$31.14
$21.40
PFE.N
About
Overall
| Beta: | 0.75 |
| Market Cap (Mil.): | $206,483.70 |
| Shares Outstanding (Mil.): | 7,093.22 |
| Dividend: | 0.24 |
| Yield (%): | 3.30 |
Financials
| PFE.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 20.63 | 34.14 | 34.28 |
| EPS (TTM): | 1.41 | -- | -- |
| ROI: | 6.65 | 19.49 | 18.85 |
| ROE: | 12.71 | 20.26 | 19.72 |
RPT-FEATURE-Pfizer takes its shot at a vaccine for evasive superbug
CHICAGO, May 23 - Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.
Pfizer takes its shot at a vaccine for evasive superbug
CHICAGO - Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.
Pfizer to spin off Zoetis stake to shareholders
- Pfizer Inc said on Wednesday it will spin off its majority stake in animal health business Zoetis Inc to shareholders by allowing them to swap Pfizer stock for Zoetis shares at a 7 percent discount.
UPDATE 2-Pfizer to spin off Zoetis stake to shareholders
May 22 - Pfizer Inc said on Wednesday it will spin off its majority stake in animal health business Zoetis Inc to shareholders by allowing them to swap Pfizer stock for Zoetis shares at a 7 percent discount.
BRIEF-Pfizer up in premarket after plans to unwind remaining majority stake in Zoetis
NEW YORK, May 22 - Pfizer Inc : * Up 2.2 percent to $29.40 in premarket after plans to unwind remaining majority stake in Zoetis
Pfizer halts study of lymphoma drug unlikely to help survival
- Pfizer Inc, which has been on a hot streak with three recent approvals of cancer drugs, stumbled on Monday, saying it was halting a late-stage trial of a drug for aggressive non-Hodgkin lymphoma after independent monitors found it was not likely to improve survival.
Pfizer yet to decide on Pain Therapeutics' painkiller
- Pfizer Inc said it could not decide whether to pursue regulatory approval for Pain Therapeutics Inc's painkiller Remoxy, for which the United States Food and Drug Administration sought additional studies.
REUTERS SUMMIT-Drug industry CEOs plotting more carve-outs
(For other news from Reuters Health Summit, click on http://www.reuters.com/summit/Health13)
Pfizer results fall short; company trims profit forecast
- Pfizer Inc reported much lower-than-expected first-quarter sales on Tuesday, hurt by weak demand for its Prevnar 13 vaccine used to prevent pneumonia and other infections, and it trimmed its 2013 profit forecast.
UPDATE 4-Pfizer results fall short; company trims profit forecast
April 30 - Pfizer Inc reported much lower-than-expected first-quarter sales on Tuesday, hurt by weak demand for its Prevnar 13 vaccine used to prevent pneumonia and other infections, and it trimmed its 2013 profit forecast.
Competitors
| Price | Change | |
|---|---|---|
| The Procter & Gamble Company (PG.N) | $78.70 | -0.12 |
| Johnson & Johnson (JNJ.N) | $87.21 | -0.59 |
| Novartis AG (NOVN.VX) | CHF71.50 | +0.05 |
| Merck & Co., Inc. (MRK.N) | $47.33 | +0.62 |
| Roche Holding Ltd. (ROG.VX) | CHF252.90 | +2.20 |
| Abbott Laboratories (ABT.N) | $37.48 | -0.24 |
| Bayer AG (BAYGn.DE) | €84.23 | +0.32 |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €85.27 | +0.46 |
| AstraZeneca plc (AZN.L) | 3,418.36p | -8.00 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
